Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
27.29B
Market cap27.29B
Price-Earnings ratio
-90.01
Price-Earnings ratio-90.01
Dividend yield
Dividend yield
Average volume
1.03M
Average volume1.03M
High today
$209.76
High today$209.76
Low today
$195.46
Low today$195.46
Open price
$204.53
Open price$204.53
Volume
1.34M
Volume1.34M
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

The current Natera(NTRA) stock price is $197.32, with a market capitalization of 27.29B. The stock trades at a price-to-earnings (P/E) ratio of -90.01.

On 2026-02-05, Natera(NTRA) stock traded between a low of $195.46 and a high of $209.76. Shares are currently priced at $197.32, which is +1.0% above the low and -5.9% below the high.

Natera(NTRA) shares are trading with a volume of 1.34M, against a daily average of 1.03M.

In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $125.38.

In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $125.38.

NTRA News

TipRanks 3d
Natera submits premarket approval to FDA for Signatera CDx

Natera (NTRA) announced the submission of its premarket approval, or PMA, to the FDA for Signatera CDx for detection of molecular residual disease, or MRD, in p...

Simply Wall St 5d
Assessing Natera Valuation After Recent Share Price Gains And Strong Long Term Returns

Advertisement Natera stock snapshot after recent moves Natera (NTRA) has seen mixed returns recently, with a 0.1% gain over the past month and a 16.2% rise ov...

Assessing Natera Valuation After Recent Share Price Gains And Strong Long Term Returns

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.